INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57501, 20910, 'Interferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57502, 20911, 'Interferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57503, 4034, 'Interferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57504, 18116, 'Interferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57505, 18117, 'Interferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57506, 20910, 'Interferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57507, 20911, 'Interferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57508, 4034, 'Interferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57509, 18116, 'Interferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57510, 18117, 'Interferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57511, 20910, 'Interferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57512, 20911, 'Interferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57513, 4034, 'Interferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57514, 18116, 'Interferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57515, 18117, 'Interferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57516, 20910, 'Interferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57517, 20911, 'Interferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57518, 4034, 'Interferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57519, 18116, 'Interferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57520, 18117, 'Interferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57521, 20910, 'Interferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57522, 20911, 'Interferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57523, 4034, 'Interferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57524, 18116, 'Interferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57525, 18117, 'Interferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57526, 20910, 'Interferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57527, 20911, 'Interferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57528, 4034, 'Interferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57529, 18116, 'Interferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57530, 18117, 'Interferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57531, 20910, 'Interferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57532, 20911, 'Interferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57533, 0, 'Anakinra', 'Infections', 'Anakinra has been associated with an increased incidence of serious infections in clinical trials in rheumatoid arthritis (RA).  RA therapy should be discontinued if a patient develops a serious infection.  In neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA) patients treated with anakinra, the risk of a disease flare when discontinuing this drug should be weighed against the potential risk of continued therapy.  Anakinra should not be started in patients with active infections.  Safety and efficacy have not been evaluated in immunosuppressed patients or in patients with chronic infections; caution is recommended when using anakinra in these patients.Drugs that affect the immune system by blocking tumor necrosis factor have been associated with an increased risk of reactivation of latent tuberculosis; it is possible that taking drugs that block interleukin-1 (such as anakinra) increases the risk of tuberculosis or other atypical or opportunistic infections.  The current US CDC guidelines should be followed both to evaluate for and to treat possible latent tuberculosis before starting therapy with anakinra.', '2', '"Product Information. Kineret (anakinra)." Sobi Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57534, 0, 'Anakinra', 'Liver Diseases', 'No formal studies have been conducted examining the pharmacokinetics of anakinra administered subcutaneously in patients with hepatic dysfunction.  Caution is recommended when using anakinra in these patients.', '2', '"Product Information. Kineret (anakinra)." Sobi Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57535, 0, 'Anakinra', 'Neutropenia', 'The use of anakinra has been associated with a decrease in neutrophil counts.  Neutrophil counts should be assessed prior to initiating therapy and while receiving therapy, monthly for 3 months and thereafter quarterly for up to 1 year.', '2', '"Product Information. Kineret (anakinra)." Sobi Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57536, 0, 'Anakinra', 'Kidney Diseases', 'Anakinra is substantially excreted by the kidney.  The risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Administration of the prescribed dose every other day should be considered for patients who have severe renal dysfunction or end-stage renal disease (defined as CrCl less than 30 mL/min [as estimated from serum creatinine levels]).  Caution should be exercised when using anakinra in these patients.', '2', '"Product Information. Kineret (anakinra)." Sobi Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57537, 6212, 'Insulin lispro', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', '"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation  (2014):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57538, 20551, 'Insulin lispro', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', '"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation  (2014):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57539, 20552, 'Insulin lispro', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', '"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation  (2014):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57540, 6212, 'Insulin lispro', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', '"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation  (2014):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57541, 20551, 'Insulin lispro', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', '"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation  (2014):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57542, 20552, 'Insulin lispro', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', '"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation  (2014):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57543, 6212, 'Insulin lispro', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57544, 20551, 'Insulin lispro', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57545, 20552, 'Insulin lispro', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57546, 20894, 'Interferon alfacon-1', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57547, 20894, 'Interferon alfacon-1', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57548, 20894, 'Interferon alfacon-1', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57549, 20894, 'Interferon alfacon-1', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57550, 20894, 'Interferon alfacon-1', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57551, 20894, 'Interferon alfacon-1', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57552, 20894, 'Interferon alfacon-1', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57553, 20894, 'Interferon alfacon-1', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57554, 20894, 'Interferon alfacon-1', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57555, 20894, 'Interferon alfacon-1', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57556, 14775, 'Interferon beta-1a', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57557, 25748, 'Interferon beta-1a', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57558, 25749, 'Interferon beta-1a', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57559, 25750, 'Interferon beta-1a', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57560, 14775, 'Interferon beta-1a', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57561, 25748, 'Interferon beta-1a', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57562, 25749, 'Interferon beta-1a', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57563, 25750, 'Interferon beta-1a', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57564, 14775, 'Interferon beta-1a', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57565, 25748, 'Interferon beta-1a', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57566, 25749, 'Interferon beta-1a', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57567, 25750, 'Interferon beta-1a', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57568, 14775, 'Interferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57569, 25748, 'Interferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57570, 25749, 'Interferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57571, 25750, 'Interferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57572, 0, 'Iodide I-123', 'Kidney Diseases', 'Sodium iodide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.', '2', '"Product Information. Iodopen (sodium iodide)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57573, 13201, 'Inulin', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57574, 27441, 'Inulin', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57575, 13201, 'Inulin', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57576, 27441, 'Inulin', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57577, 20894, 'Interferon gamma-1b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57578, 20894, 'Interferon gamma-1b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57579, 20894, 'Interferon gamma-1b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57580, 20894, 'Interferon alfa-n3', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57581, 20894, 'Interferon alfa-n3', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57582, 20894, 'Interferon alfa-n3', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57583, 20894, 'Interferon alfa-n3', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57584, 20894, 'Interferon alfa-n3', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57585, 20894, 'Interferon alfa-n3', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57586, 20894, 'Interferon alfa-n3', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57587, 20894, 'Interferon alfa-n3', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57588, 20894, 'Interferon alfa-n3', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57589, 20894, 'Interferon alfa-n3', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57590, 5345, 'Anastrozole', 'Cardiovascular Diseases', 'In studies of women with preexisting ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with the use of anastrozole.  Caution should be exercised when prescribing anastrozole to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57591, 14107, 'Anastrozole', 'Cardiovascular Diseases', 'In studies of women with preexisting ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with the use of anastrozole.  Caution should be exercised when prescribing anastrozole to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57592, 14108, 'Anastrozole', 'Cardiovascular Diseases', 'In studies of women with preexisting ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with the use of anastrozole.  Caution should be exercised when prescribing anastrozole to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57593, 14109, 'Anastrozole', 'Cardiovascular Diseases', 'In studies of women with preexisting ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with the use of anastrozole.  Caution should be exercised when prescribing anastrozole to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57594, 14391, 'Anastrozole', 'Cardiovascular Diseases', 'In studies of women with preexisting ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with the use of anastrozole.  Caution should be exercised when prescribing anastrozole to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57595, 5345, 'Anastrozole', 'Hypercholesterolemia', 'During a clinical trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).  Caution should be taken when this agent is prescribed to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57596, 14107, 'Anastrozole', 'Hypercholesterolemia', 'During a clinical trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).  Caution should be taken when this agent is prescribed to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57597, 14108, 'Anastrozole', 'Hypercholesterolemia', 'During a clinical trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).  Caution should be taken when this agent is prescribed to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57598, 14109, 'Anastrozole', 'Hypercholesterolemia', 'During a clinical trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).  Caution should be taken when this agent is prescribed to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57599, 14391, 'Anastrozole', 'Hypercholesterolemia', 'During a clinical trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).  Caution should be taken when this agent is prescribed to these patients.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57600, 5345, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', 'Lonning PE, Geisler J, Dowsett M "Pharmacological and clinical profile of anastrozole." Breast Cancer Res Treat 49 (1998):  s53-7|"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57601, 14107, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', 'Lonning PE, Geisler J, Dowsett M "Pharmacological and clinical profile of anastrozole." Breast Cancer Res Treat 49 (1998):  s53-7|"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57602, 14108, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', 'Lonning PE, Geisler J, Dowsett M "Pharmacological and clinical profile of anastrozole." Breast Cancer Res Treat 49 (1998):  s53-7|"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57603, 14109, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', 'Lonning PE, Geisler J, Dowsett M "Pharmacological and clinical profile of anastrozole." Breast Cancer Res Treat 49 (1998):  s53-7|"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57604, 14391, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', 'Lonning PE, Geisler J, Dowsett M "Pharmacological and clinical profile of anastrozole." Breast Cancer Res Treat 49 (1998):  s53-7|"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57605, 5345, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57606, 14107, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57607, 14108, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57608, 14109, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57609, 14391, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '"Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57610, 26632, 'Iodine (topical)', 'Thyroid Hormone Metabolism, Abnormal', 'Elevated serum iodine levels can lead to altered thyroid function and metabolic abnormalities in patients receiving oral iodine therapy as well as topical therapy.  Iodine should be used cautiously in patients with thyroid disorders.  Monitoring thyroid function is recommended.', '2', '"Product Information. Betadine (povidone iodine topical)." Akorn Inc|"Product Information. Betadine (povidone iodine topical)." Purdue Frederick Company|"Product Information. Iodopen (sodium iodide)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57611, 0, 'Iodide I-131', 'Kidney Diseases', 'Sodium iodide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.', '2', '"Product Information. Iodopen (sodium iodide)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57612, 0, 'Iodide I-131', 'Bone Marrow Failure Disorders', 'Sodium iodide-I-131 administered at doses used for thyroid chemotherapy induces myelosuppression including anemia, leukopenia, and thrombocytopenia.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with sodium iodide-I-131 should be administered cautiously in patients with compromised bone marrow reserve.  Clinical monitory of hematopoietic function is recommended.', '2', '"Product Information. Sodium Iodide 1-131 (sodium iodide I-131)." Mallinckrodt Medical Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57613, 12375, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57614, 12376, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57615, 29436, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57616, 29437, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57617, 29438, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57618, 12375, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57619, 12376, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57620, 29436, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57621, 29437, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57622, 29438, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57623, 12375, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57624, 12376, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57625, 29436, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57626, 29437, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57627, 29438, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57628, 12375, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):|"Product Information. Hexabrix 200 (ioxaglate)." Tyco Healthcare Group Canada Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57629, 12376, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):|"Product Information. Hexabrix 200 (ioxaglate)." Tyco Healthcare Group Canada Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57630, 29436, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):|"Product Information. Hexabrix 200 (ioxaglate)." Tyco Healthcare Group Canada Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57631, 29437, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):|"Product Information. Hexabrix 200 (ioxaglate)." Tyco Healthcare Group Canada Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57632, 29438, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):|"Product Information. Hexabrix 200 (ioxaglate)." Tyco Healthcare Group Canada Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57633, 12375, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57634, 12376, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57635, 29436, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57636, 29437, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57637, 29438, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57638, 12375, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57639, 12376, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57640, 29436, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57641, 29437, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57642, 29438, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57643, 12375, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57644, 12376, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57645, 29436, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57646, 29437, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57647, 29438, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57648, 0, 'Iobenguane (I-123)', 'Hypertension', 'Iobenguane I-123 may increase release of norepinephrine from chromaffin granules and produce a transient episode of hypertension.  It is recommended to assess the patient''s pulse and blood pressure before and intermittently for 30 minutes after iobenguane I-123 administration.  Care should be exercised when using this agent in patients with hypertension.  Prior to Iobenguane I-123 administration, ensure emergency cardiac and anti-hypertensive treatments are readily available.', '2', '"Product Information. AdreView (iobenguane I-123)." GE Healthcare  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57649, 0, 'Iobenguane (I-123)', 'Parkinson Disease', 'Individuals with conditions that affect the sympathetic nervous system, e.g., Parkinsonian syndromes such as Parkinson''s disease or multiple system atrophy, may show decreased cardiac uptake of iobenguane I-123 independent of heart disease.', '2', '"Product Information. AdreView (iobenguane I-123)." GE Healthcare  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57650, 0, 'Iobenguane (I-123)', 'Kidney Diseases', 'Iobenguane I-123 is cleared by the kidneys and is not dialyzable.  When iobenguane I-123 is used in patients with severe renal impairment, the radiation dose may be increased due to delayed elimination of the drug which may also reduce the target to background rations and decrease the quality of scintigraphic images.  Care should be exercised when using this agent in patients with severe renal impairment as the safety and efficacy have not been established in these patients.  It is recommended to consider assessment of renal function in patients prior to iobenguane I-123 administration.', '2', '"Product Information. AdreView (iobenguane I-123)." GE Healthcare  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57651, 3304, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57652, 3319, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57653, 11881, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57654, 11882, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57655, 0, 'Ipecac', 'Pneumonia, Aspiration', 'Ipecac induces vomiting of gastrointestinal contents that can be aspirated.  Therapy with ipecac should not be administered to patients who are less than fully conscious, severely intoxicated, in shock, having seizures, or lack gag reflexes.', '3', '"Product Information. Ipecac (ipecac)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57656, 0, 'Ipecac', 'Cardiomyopathies', 'Ipecac may be absorbed if vomiting does not take place.  Cardiotoxicity such as tachycardia, hypotension, dyspnea, ECG changes or arrhythmia have occurred.  Chronic use to induce vomiting by patients with eating disorders has resulted in myocarditis, cardiac arrest and failure.  Therapy with ipecac should be administered cautiously in patients with or predisposition to cardiovascular dysfunction.', '2', '"Product Information. Ipecac (ipecac)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57657, 0, 'Ipecac', 'Vascular Diseases', 'Ipecac induced vomiting can increase blood pressure.  Vomiting and retching associated with ipecac therapy may increase the risk of hemorrhage in patients with sclerotic or other pathologic changes in blood vessels.  Therapy with ipecac should be administered cautiously in patients with altered vascular physiology.', '2', '"Product Information. Ipecac (ipecac)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57658, 0, 'Ioxilan', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57659, 0, 'Ioxilan', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57660, 24177, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57661, 24178, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57662, 24179, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57663, 24180, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57664, 24181, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57665, 24177, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57666, 24178, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57667, 24179, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57668, 24180, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57669, 24181, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Hypaque (diatrizoate)." Amersham Health  (2007):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb  (2015):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57670, 24177, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57671, 24178, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57672, 24179, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57673, 24180, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57674, 24181, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57675, 24177, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57676, 24178, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57677, 24179, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57678, 24180, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57679, 24181, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '"Product Information. Visipaque (iodixanol)." Nycomed Inc  (2001):|"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):|"Product Information. Oxilan (ioxilan)." Guerbet LLC  (2006):|"Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc  (2007):|"Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57680, 24177, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57681, 24178, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57682, 24179, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57683, 24180, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57684, 24181, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57685, 24177, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57686, 24178, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57687, 24179, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57688, 24180, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57689, 24181, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57690, 24177, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57691, 24178, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57692, 24179, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57693, 24180, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57694, 24181, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '"Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57695, 1116, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57696, 1117, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57697, 11376, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57698, 12144, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57699, 20934, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57700, 20935, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57701, 30164, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57702, 30165, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57703, 1116, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57704, 1117, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57705, 11376, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57706, 12144, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57707, 20934, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57708, 20935, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57709, 30164, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57710, 30165, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57711, 1116, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57712, 1117, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57713, 11376, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57714, 12144, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57715, 20934, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57716, 20935, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57717, 30164, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57718, 30165, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57719, 31636, 'Ipilimumab', 'Colitis', 'Ipilimumab can cause immune-mediated colitis, which may be fatal.  CMV infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis; repeating infectious workup should be considered in these patients to exclude alternative etiologies.  Ipilimumab should be withheld or permanently discontinued depending on severity of colitis.', '3', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57720, 31636, 'Ipilimumab', 'Dermatitis', 'Ipilimumab can cause immune-mediated rash or dermatitis (including bullous and exfoliative dermatitis, Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], and drug rash with eosinophilia and systemic symptoms [DRESS]).  Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes.  Ipilimumab should be withheld for suspected SJS, TEN, or DRESS and permanently discontinued for confirmed SJS, TEN, or DRESS.', '3', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57721, 31636, 'Ipilimumab', 'Endocrine System Diseases', 'Immune-mediated endocrinopathies, including severe to life-threatening cases, have occurred with ipilimumab therapy.  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.  Clinical chemistries (including adrenocorticotropic hormone [ACTH] level and thyroid function) should be evaluated at baseline and before each dose.  Medical management should be started promptly, including specialty consultation as appropriate.  Ipilimumab should be withheld or permanently discontinued depending on severity of endocrinopathies.', '3', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57722, 31636, 'Ipilimumab', 'Hepatitis', 'Ipilimumab can cause immune-mediated adverse reactions, which may be severe or fatal.  Immune-mediated hepatitis has occurred with ipilimumab therapy.  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.  Clinical chemistries (including liver enzymes) should be evaluated at baseline and before each dose.  Ipilimumab should be withheld or permanently discontinued depending on severity of hepatitis.', '3', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57723, 31636, 'Ipilimumab', 'Graft vs Host Disease', 'Fatal or serious graft-versus-host disease (GVHD) can occur in patients who receive ipilimumab either before or after allogeneic hematopoietic stem cell transplantation (HSCT).  These complications may occur despite intervening therapy between cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor blocking antibody and allogeneic HSCT.  It is recommended to monitor patients closely for evidence of GVHD and intervene promptly.  The benefit versus risks of treatment with ipilimumab after allogeneic HSCT should be considered.', '3', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57724, 31636, 'Ipilimumab', 'Immune System Diseases', 'Ipilimumab can cause immune-mediated adverse reactions, which may be severe or fatal.  Immune-mediated adverse reactions can occur in any organ system or tissue.  Care should be exercised when using ipilimumab in patients with preexisting immune system disorders (e.g., ulcerative colitis, Crohn''s disease, lupus).  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.  Clinical chemistries (including liver enzymes, creatinine, adrenocorticotropic hormone [ACTH] level, and thyroid function) should be evaluated at baseline and before each dose.  Medical management should be started promptly, including specialty consultation as appropriate.  Ipilimumab should be withheld or permanently discontinued depending on severity.', '3', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57725, 31636, 'Ipilimumab', 'Eye Diseases', 'Ipilimumab can cause immune-mediated adverse reactions, which may be severe or fatal.  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.  Ipilimumab should be permanently discontinued for a Grade 2, 3, or 4 ophthalmologic adverse reaction that does not improve to Grade 1 within 2 weeks while receiving topical therapy or if systemic therapy is required.', '3', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57726, 31636, 'Ipilimumab', 'Hepatic Insufficiency', 'Care should be exercised when using ipilimumab in patients with moderate (total bilirubin greater than 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN] and any AST) or severe (total bilirubin greater than 3 x ULN and any AST) liver dysfunction as ipilimumab has not been studied in these patients.  Mild liver dysfunction (total bilirubin greater than 1 to 1.5 x ULN or AST greater than ULN) had no clinically significant effect on the clearance of ipilimumab.', '2', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57727, 31636, 'Ipilimumab', 'Pneumonia', 'Ipilimumab can cause immune-mediated pneumonitis.  Care should be exercised when using ipilimumab in patients with preexisting pulmonary impairment.  Ipilimumab should be withheld or permanently discontinued depending on severity of pneumonitis.', '2', '"Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb  (2023):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57728, 18027, 'Anidulafungin', 'Liver Diseases', 'Laboratory abnormalities in liver function tests have been observed in healthy volunteers and patients treated with echinocandins, and clinical hepatic abnormalities have occurred in some patients with serious underlying conditions who were receiving multiple concomitant medications with echinocandin therapy.  Isolated cases of significant hepatic dysfunction, hepatitis, or worsening hepatic failure have also been reported, although a causal relationship has not been established.  Therapy with echinocandins should be administered cautiously in patients with preexisting liver disease.  Liver function should be monitored regularly during therapy.', '2', '"Product Information. Cancidas (caspofungin)." Merck & Co., Inc  (2001):|"Product Information. Mycamine (micafungin)." Fujisawa  (2005):|"Product Information. Eraxis (anidulafungin)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57729, 1116, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57730, 1117, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57731, 11376, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57732, 12144, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57733, 20934, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57734, 20935, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57735, 30164, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57736, 30165, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57737, 1408, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57738, 1784, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57739, 1827, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57740, 1852, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57741, 1883, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57742, 3088, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57743, 4215, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57744, 4663, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57745, 4813, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57746, 4814, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57747, 4859, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57748, 5394, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57749, 5862, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57750, 6287, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57751, 6288, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57752, 6694, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57753, 6826, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57754, 6933, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57755, 8209, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57756, 10139, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57757, 11112, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57758, 11403, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57759, 14060, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57760, 14204, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57761, 15171, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57762, 15173, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57763, 17014, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57764, 17974, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57765, 18649, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57766, 18982, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57767, 18996, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57768, 19254, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57769, 20005, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57770, 20006, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57771, 20168, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57772, 20170, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57773, 20173, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57774, 20175, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57775, 20176, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57776, 20606, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57777, 20895, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57778, 20970, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57779, 21834, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57780, 25047, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57781, 27837, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57782, 28533, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57783, 33550, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57784, 1408, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57785, 1784, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57786, 1827, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57787, 1852, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57788, 1883, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57789, 3088, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57790, 4215, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57791, 4663, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57792, 4813, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57793, 4814, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57794, 4859, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57795, 5394, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57796, 5862, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57797, 6287, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57798, 6288, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57799, 6694, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57800, 6826, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57801, 6933, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57802, 8209, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57803, 10139, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57804, 11112, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57805, 11403, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57806, 14060, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57807, 14204, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57808, 15171, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57809, 15173, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57810, 17014, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57811, 17974, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57812, 18649, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57813, 18982, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57814, 18996, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57815, 19254, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57816, 20005, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57817, 20006, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57818, 20168, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57819, 20170, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57820, 20173, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57821, 20175, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57822, 20176, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57823, 20606, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57824, 20895, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57825, 20970, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57826, 21834, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57827, 25047, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57828, 27837, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57829, 28533, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57830, 33550, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57831, 1408, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57832, 1784, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57833, 1827, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57834, 1852, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57835, 1883, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57836, 3088, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57837, 4215, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57838, 4663, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57839, 4813, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57840, 4814, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57841, 4859, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57842, 5394, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57843, 5862, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57844, 6287, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57845, 6288, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57846, 6694, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57847, 6826, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57848, 6933, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57849, 8209, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57850, 10139, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57851, 11112, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57852, 11403, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57853, 14060, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57854, 14204, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57855, 15171, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57856, 15173, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57857, 17014, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57858, 17974, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57859, 18649, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57860, 18982, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57861, 18996, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57862, 19254, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57863, 20005, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57864, 20006, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57865, 20168, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57866, 20170, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57867, 20173, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57868, 20175, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57869, 20176, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57870, 20606, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57871, 20895, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57872, 20970, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57873, 21834, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57874, 25047, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57875, 27837, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57876, 28533, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57877, 33550, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982):  248-9|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57878, 1408, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57879, 1784, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57880, 1827, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57881, 1852, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57882, 1883, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57883, 3088, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57884, 4215, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57885, 4663, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57886, 4813, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57887, 4814, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57888, 4859, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57889, 5394, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57890, 5862, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57891, 6287, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57892, 6288, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57893, 6694, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57894, 6826, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57895, 6933, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57896, 8209, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57897, 10139, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57898, 11112, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57899, 11403, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57900, 14060, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57901, 14204, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57902, 15171, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57903, 15173, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57904, 17014, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57905, 17974, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57906, 18649, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57907, 18982, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57908, 18996, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57909, 19254, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57910, 20005, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57911, 20006, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57912, 20168, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57913, 20170, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57914, 20173, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57915, 20175, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57916, 20176, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57917, 20606, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57918, 20895, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57919, 20970, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57920, 21834, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57921, 25047, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57922, 27837, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57923, 28533, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57924, 33550, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57925, 1408, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57926, 1784, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57927, 1827, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57928, 1852, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57929, 1883, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57930, 3088, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57931, 4215, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57932, 4663, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57933, 4813, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57934, 4814, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57935, 4859, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57936, 5394, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57937, 5862, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57938, 6287, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57939, 6288, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57940, 6694, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57941, 6826, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57942, 6933, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57943, 8209, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57944, 10139, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57945, 11112, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57946, 11403, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57947, 14060, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57948, 14204, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57949, 15171, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57950, 15173, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57951, 17014, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57952, 17974, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57953, 18649, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57954, 18982, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57955, 18996, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57956, 19254, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57957, 20005, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57958, 20006, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57959, 20168, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57960, 20170, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57961, 20173, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57962, 20175, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57963, 20176, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57964, 20606, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57965, 20895, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57966, 20970, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57967, 21834, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57968, 25047, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57969, 27837, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57970, 28533, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57971, 33550, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988):  346-7|Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966):  745-8|Jacobs J "Death due to iron parenterally." South Med J 62 (1969):  p216assim|Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982):  341-2|Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979):  178|Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990):  166-8|Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969):  645-6|Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975):  326-33|Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990):  162-6|"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57972, 1408, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57973, 1784, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57974, 1827, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57975, 1852, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57976, 1883, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57977, 3088, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57978, 4215, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57979, 4663, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57980, 4813, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57981, 4814, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57982, 4859, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57983, 5394, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57984, 5862, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57985, 6287, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57986, 6288, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57987, 6694, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57988, 6826, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57989, 6933, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57990, 8209, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57991, 10139, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57992, 11112, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57993, 11403, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57994, 14060, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57995, 14204, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57996, 15171, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57997, 15173, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57998, 17014, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57999, 17974, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58000, 18649, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. DexFerrum (iron dextran)." American Regent Laboratories Inc  (2015):', 'DDInter', 0);
